BioCardia, Henry Ford Health Begin Phase 3 Cell Therapy Trial
In BioCardia’s prior CardiAMP-HF study, the composite primary endpoint was achieved with statistical significance in the subgroup of ischemic...
Ernexa Therapeutics Reports Strong Q Performance, Cell Trials
Ernexa reported a 58.2% survival advantage in preclinical models for its ovarian cancer program, ERNA-101, and a 44% year-over-year...
New Data: Rezdiffra Shows Promising MASH Cirrhosis Results
Two-year open-label data from the MAESTRO-NAFLD-1 compensated cirrhosis arm (F4c) reported a mean reduction in liver stiffness by VCTE...
Clearmind Completes First Cohort in Alcohol Use Disorder Trial
Clearmind Medicine has completed dosing in the first cohort of its Phase I/IIa trial of CMND-100 for alcohol use...
SpyGlass Pharma’s Remarkable, Positive 36-Month IOL Results
SpyGlass Pharma reported a 37% mean intraocular pressure reduction at 36 months in its first-in-human study of the bimatoprost...
NEK7 Degrader MRT-8102 Shows Promise in Preclinical Data
Preclinical data presented at AHA 2025 show MRT-8102, an oral NEK7-directed molecular glue degrader, selectively degrades NEK7, suppresses NLRP3...
Telitacicept Hits Endpoint in Phase 3 IgA Nephropathy Trial
Telitacicept reduced the 24-hour urine protein-to-creatinine ratio by 58.9% at Week 39, compared with an 8.8% reduction on placebo...
CRISPR’s CTX310 Shows Positive Phase 1 Lipid-Lowering Data
At the highest dose in a Phase 1 trial of 15 adults with refractory dyslipidemia, a single intravenous course...
Bioversys’ Important BV100 Phase 2b Trial Gets Wellcome Fund
BV100 will advance to an open-label, randomized Phase 2b trial for carbapenem-resistant Acinetobacter baumannii infections, with 90 evaluable patients...
Medera Presents Promising New Heart Failure Gene Therapy Data
Interim results from Medera’s MUSIC-HFpEF Phase 1/2a study reported no gene therapy–related serious adverse events among 10 treated patients,...